Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review

Standard

Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. / Starshinova, Anna ; Malkova, Anna ; Zinchenko, Ulia ; Kudlay , Dmitry ; Glushkova, Anzhela ; Dovgalyk , Irina ; Yablonskiy, Piotr ; Shoenfeld, Yehuda .

в: Life, Том 11, № 8, 753, 08.2021.

Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование

BibTeX

@article{c98218f20e744fc4af7aab9180efe100,

title = "Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review",

abstract = "A new coronavirus disease (COVID-19) has already affected millions of people in 213 countries. The possibilities of treatment have been reviewed in recent publications but there are many controversial results and conclusions. An analysis of the studies did not reveal a difference in mortality level between people treated with standard therapy, such as antiviral drugs and dexamethasone, and new antiviral drugs/additional immune therapy. However, most studies describe clinical improvement and a decrease in mortality among patients with severe and critical conditions, with the early initiation of additional immune therapy. Possible new targets based on viral life cycles were considered. Unfortunately, the data analysis on the efficacy of different medicine and therapy regimens among patients with COVID-19, showed little success in decreasing the mortality rate in all treatment methods. Some efficacy has been shown with an immunosuppressive therapy in small patient samples, but when a larger number of patients were analyzed the data did not differ significantly from the control groups.",

keywords = "coronavirus infection, Sars-coV-2, COVID-19, antiviral therapy, immune therapy, Cytokines, plasma, intravenous immunoglobulin IgG, Plasma, Antiviral therapy, Coronavirus infection, Intravenous immunoglobulin IgG, SARS-CoV-2, Immune therapy, CELLS, MULTICENTER, PROTEIN, SARS CORONAVIRUS, cytokines, CONVALESCENT PLASMA, EXPRESSION",

author = "Anna Starshinova and Anna Malkova and Ulia Zinchenko and Dmitry Kudlay and Anzhela Glushkova and Irina Dovgalyk and Piotr Yablonskiy and Yehuda Shoenfeld",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

doi = "10.3390/life11080753",

language = "English",

volume = "11",

journal = "Life",

issn = "0024-3019",

publisher = "MDPI AG",

number = "8",

}

RIS

TY - JOUR

T1 - Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review

AU - Starshinova, Anna

AU - Malkova, Anna

AU - Zinchenko, Ulia

AU - Kudlay , Dmitry

AU - Glushkova, Anzhela

AU - Dovgalyk , Irina

AU - Yablonskiy, Piotr

AU - Shoenfeld, Yehuda

PY - 2021/8

Y1 - 2021/8

N2 - A new coronavirus disease (COVID-19) has already affected millions of people in 213 countries. The possibilities of treatment have been reviewed in recent publications but there are many controversial results and conclusions. An analysis of the studies did not reveal a difference in mortality level between people treated with standard therapy, such as antiviral drugs and dexamethasone, and new antiviral drugs/additional immune therapy. However, most studies describe clinical improvement and a decrease in mortality among patients with severe and critical conditions, with the early initiation of additional immune therapy. Possible new targets based on viral life cycles were considered. Unfortunately, the data analysis on the efficacy of different medicine and therapy regimens among patients with COVID-19, showed little success in decreasing the mortality rate in all treatment methods. Some efficacy has been shown with an immunosuppressive therapy in small patient samples, but when a larger number of patients were analyzed the data did not differ significantly from the control groups.

AB - A new coronavirus disease (COVID-19) has already affected millions of people in 213 countries. The possibilities of treatment have been reviewed in recent publications but there are many controversial results and conclusions. An analysis of the studies did not reveal a difference in mortality level between people treated with standard therapy, such as antiviral drugs and dexamethasone, and new antiviral drugs/additional immune therapy. However, most studies describe clinical improvement and a decrease in mortality among patients with severe and critical conditions, with the early initiation of additional immune therapy. Possible new targets based on viral life cycles were considered. Unfortunately, the data analysis on the efficacy of different medicine and therapy regimens among patients with COVID-19, showed little success in decreasing the mortality rate in all treatment methods. Some efficacy has been shown with an immunosuppressive therapy in small patient samples, but when a larger number of patients were analyzed the data did not differ significantly from the control groups.

KW - coronavirus infection

KW - Sars-coV-2

KW - COVID-19

KW - antiviral therapy

KW - immune therapy

KW - Cytokines

KW - plasma

KW - intravenous immunoglobulin IgG

KW - Plasma

KW - Antiviral therapy

KW - Coronavirus infection

KW - Intravenous immunoglobulin IgG

KW - SARS-CoV-2

KW - Immune therapy

KW - CELLS

KW - MULTICENTER

KW - PROTEIN

KW - SARS CORONAVIRUS

KW - cytokines

KW - CONVALESCENT PLASMA

KW - EXPRESSION

UR - http://www.scopus.com/inward/record.url?scp=85111747221&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/5f034f49-f5c0-3889-890b-65147d7677dd/

U2 - 10.3390/life11080753

DO - 10.3390/life11080753

M3 - Review article

C2 - 34440497

VL - 11

JO - Life

JF - Life

SN - 0024-3019

IS - 8

M1 - 753

ER -

ID: 85023289

Standard

Harvard

APA

Vancouver

Author

BibTeX

RIS